Metreleptin

(Myalept®)

Myalept®

Drug updated on 11/10/2023

Dosage FormInjection (subcutaneous; sterile, white, solid, lyophilized cake of 11.3 mg metreleptin per vial to deliver 5 mg per mL when reconstituted in 2.2 mL of BWFI or WFI)
Drug ClassLeptin analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Product Monograph / Prescribing Information

Document TitleYearSource
Myalept (metreleptin) Prescribing Information.2022Amryt Pharmaceuticals DAC, Dublin, Ireland

Systematic Reviews / Meta-Analyses